BNET Industries
Last Fiscal Year Sales:$1.0M
- Public
- US
Dow Jones Description
We are a medical technology company, incorporated in 1992, focused on developing innovative medical devices that have the potential to improve health care. Currently, we are conducting research, development and marketing of products for the diabetes management market and developing a product for the non-invasive cancer diagnostics market. Prior to 2001, our technology was primarily based upon biophotonic technology, which we define as the use of light and other forms of energy to access the human body to diagnose and monitor disease. We added sterile disposable products and technology for insulin delivery to our technology base with the purchase of Sterling Medivations, Inc., now doing business as SimpleChoice, in December of 2001. Our technology, including products in research and development, includes: a) innovative methods of delivering insulin to people with diabetes with our SimpleChoice product line, b) innovative methods of sampling interstitial fluid using laser energy to create micropores for improved glucose and alcohol monitoring and c) biophotonics technology for the non-invasive detection of cancers.
President, Chief Executive Officer, Acting Chief Financial Officer and Director
Mark L FaupelNumber of Employees 74
Contact Information
4955 Avalon Ridge Pkwy
Suite 300
Norcross, Georgia 30071
7702428723
Peer Companies
NAICS Code Electromedical and Electrotherapeutic Apparatus Manufacturing: 334510
News & Analysis
Filter by
spectrx inc. and welch allyn inc. - All News and Analysis
Study Shows Welch Allyn/SpectRx Non-Invasive Cervical Cancer Prototypes Detect Lesions with More Accuracy Than Pap Tests
Business Editors PARIS--BUSINESS WIRE--April 6, 2000 Welch Allyn, Inc. and SpectRx, Inc. (NASDAQ: SPRX) announced today that the companies' prototype non-invasive cervical cancer detection devices found 31 percent more cervical precancerous lesions than conventional Pap tests in studies conducted at two U.S. research centers. In the study,...
Welch Allyn and SpectRx Report Positive Data From Non-Invasive Cervical Cancer Detection Prototypes
SKANEATELES FALLS, N.Y. and NORCROSS, Ga.--BUSINESS WIRE-- Aug. 3, 1999-- Prototype devices identify lesions missed by conventional technology Welch Allyn, Inc. and SpectRx, Inc. (NASDAQ: SPRX) announced today that prototype non-invasive cervical cancer detection devices developed by the two companies have shown the potential to identify...
Welch Allyn and SpectRx Enter Definitive Agreement to Develop Non-invasive Cancer Detection Products
SKANEATELES FALLS, NY and NORCROSS, Ga.--BUSINESS WIRE--Feb. 8, 1999--Welch Allyn, Inc. and SpectRx, Inc. (Nasdaq: SPRX) announced today they have signed a definitive agreement to jointly research, develop, and market non-invasive cervical and skin cancer diagnostic products. The companies will use SpectRx's proprietary biophotonic technology to identify cancers painlessly...
Welch Allyn and SpectRx Announce Agreement to Develop Non-invasive Cancer Detection Products
SKANEATELES FALLS, N.Y. and NORCROSS, Ga.--BUSINESS WIRE--Nov. 11, 1998--Welch Allyn, Inc. and SpectRx, Inc. (Nasdaq:SPRX) announced today they have signed a letter of intent to jointly research, develop, and market non-invasive cervical and skin cancer diagnostic products. The companies will use SpectRx's proprietary biophotonic technology to identify cancers painlessly...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Mark L Faupel | President, Chief Executive Officer, Acting Chief Financial Officer and Director |
| Siraj Noorani | Chief accounting officer and controller |
| Shabbir Bakir Bambot | V.P. of R & D |
| Walter J Pavlicek | Vice President of Operations |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| William E Zachary Jr | Acting Chairman and Director |
| Michael C James | Chairman |
| Francisco Garcia | Board of Directors |
| John E Imhoff | Board of Directors |
| Ronald W Hart | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | President, Chief Executive Officer, Acting Chief Financial Officer and Director | Current |
| Guided Therapeutics, Inc | President, Chief Executive Officer, Acting Chief Financial Officer and Director | Current |
| Spectrx, Inc. | Executive Vice President and Chief Technical Officer | Former |
| Biofield Corp | Vice President of Research and Development | Former |
| Biofield Corp | Co-Founder | Former |
| Biofield Corp | Senior Executive | Former |
| The University of Georgia | Ph.D. In Neuroanatomy and Physiology | Former |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | Chief accounting officer and controller | Current |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | V.P. of R & D | Current |
Dr. Pavlicek leads the engineering team in the design and development activities required in the commercialization of SpectRx's biophotonic medical devices. Engineering activities include optics, software, electrical, mechanical and systems. Dr. Pavlicek has over 18 years of engineering management experience. His engineering diagnostic experience has involved the commercialization of urinalysis instrumentation at Bayer and diabetes products at Roche. He has also held management positions at AT&T Bell Laboratories and faculty positions at several universities. Dr. Pavlicek earned his Ph.D. in mathematics from Saint Louis University.
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | Vice President of Operations | Current |
| Guided Therapeutics, Inc | Vice President of Operations | Current |
| Boehringer Mannheim | Executive | Former |
| Saint Louis University | Ph.D. In Mathematics | Former |
| University of San Francisco | Ph.D. | Former |
| Saint Louis University | M.S. | Former |
| University of San Francisco | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | Acting Chairman and Director | Current |
| Organization | Position | Status |
|---|---|---|
| Guided Therapeutics, Inc | Chairman | Current |
| Spectrx, Inc. | Chairman | Current |
| Guided Therapeutics, Inc | Board of Directors | Current |
| Eisner LLP | Staff Accountant | Former |
| Moore & Company Capital Management | Former | |
| Fairleigh Dickinson University | B.S. Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Easton Capital Investment Group | Managing Director, Miami Office | Current |
| Spectrx, Inc. | Board of Directors | Current |
| Easton Capital Investment Group | Board of Directors | Current |
| Kidder, Peabody & Co. | Vice President | Former |
| Cramer Rosenthal McGlynn LLC | Head of Corporate Finance | Former |
| Harvard College | AB Degree | Former |
| Harvard Law School | J. D. Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | Board of Directors | Current |
| Guided Therapeutics, Inc | Board of Directors | Current |
| Oklahoma State University | B.S. In Industrial Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Spectrx, Inc. | Board of Directors | Current |
Executive News
-
Guided Therapeutics, Inc. and Konica Minolta Opto, Inc. to Jointly Develop Cancer Detection Products
Industry Transcripts by Seeking Alpha
-
The Cooper Companies, Inc. F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 08, 2009about COO
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call Transcript
on Nov 24, 2009about MDT
-
ZOLL Medical Corporation F4Q09 (Qtr End 27/09/09) Earnings Call Transcript
on Nov 11, 2009about ZOLL
-
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
-
Cytori Therapeutics Q3 2009 Earnings Call Transcript
on Nov 09, 2009about CYTX
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Healthcare Is Still Adding Jobs, Despite Recession 3 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Beware of The Incredible Shrinking Insurance Benefit 2 votes


